NTRK1 and liver cancer: In the current study, we demonstrate that the inhibition of CD44v6 increased the susceptibility of liver cancer cells and organoids to the chemotherapeutics cisplatin and gemcitabine and the receptor tyrosine kinase inhibitors, sorafenib and regorafenib.